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Abstract
Parkinson’s  disease  (PD)  is  the  second most  common neurodegenerative  disorder
affecting approximately 1% of the population over age 50. PD is widely accepted as
a multifactorial disease with both genetic and environmental contributions. Despite
extensive research conducted in the area the precise etiological  factors responsible
remain  elusive.  In  about  95%  Parkinsonism  is  considered  to  have  a  sporadic
component.  There  are  currently  no  established  curative,  preventative,  or  disease-
modifying  interventions,  stemming  from  a  poor  understanding  of  the  molecular
mechanisms of pathogenesis. Here lies the importance of animal models. Pharmaco‐
logical insults cause Parkinsonian like phenotypes in Drosophila,  thereby modelling
sporadic  PD.  The  pesticides  paraquat  and  rotenone  induced  oxidative  damage
causing cluster specific DA neuron loss together with motor deficits. Studies in fly
PD model have deciphered that signaling pathways such as phosphatidylinositol 3-
kinase (PI3K/Akt and target of rapamycin (TOR), c-Jun N-terminal kinase (JNK) have
been  defective.  Further,  these  studies  have  demonstrated  that  fruit  fly  can  be  a
potential model to screen chemical compounds for their neuroprotective efficacy.
This chapter overviews current knowledge on the pathophysiology of sporadic PD
employing  Drosophila  model  and  discusses  the  future  perspectives.  Further  we
emphasize the importance of performing genome wide screens in fly model, which
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may lead to identification of novel pathways involved in PD, which may provide
clues to develop therapeutic strategies that help to reduce the burden of PD.
Keywords: Parkinson's disease, Drosophila, dopaminergic neurons, neurotoxicants, ge‐
nome‐wide screens
1. Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer disease, affecting approximately 1% of the population over the age of 50. Frequency
of PD increases with age, but an expected 4% of people with this disease are detected earlier
the age of 50. It is assessed that 7–10 million people worldwide are suffering from PD. About
one million Americans are surviving with PD, which is more than the collective number of
sufferers diagnosed with muscular dystrophy, Lou Gehrig's disease, and multiple sclerosis.
Further, about 60,000 Americans are diagnosed with PD each year and this number does not
mirror thousands of unnoticed cases [1]. Studies illustrate that prevalence of PD in men is
significantly higher (one and half times more) than in women. In poor and developing nations
of Asia and Africa no systematic data are available about the number of sufferers. Painful truth
is that in these regions, millions of elderly suffer in silence due to poverty and ignorance.
PD is widely accepted as a multifactorial disease with both genetic and environmental
contributions. Clinical signs comprise bradykinesia, resting tremble, muscular rigidity, and
postural unsteadiness. Supplementary symptoms are characteristic postural anomalies,
dystonic spams, and dementia. PD is progressive and usually has a devious onset in mid to
late adult life. Pathogenic characters of typical PD comprise loss of dopaminergic neurons in
the substantia nigra (SN) and the manifestation of Lewy bodies, intracellular cytoplasmic
inclusions, in enduring neurons in various areas of the brain, mainly the SN [2].
Despite intensive research conducted in the field of PD, the etiology of this neurodegenera‐
tive disease remains elusive. Although genetic elements and exposure to environmental toxins,
such as pesticides, are thought to play a crucial role in disease onset, aging remains the
predominant risk factor [3]. In about 95% patients, Parkinsonism is considered to have a
sporadic component. Some findings suggest that environmental factors may be more impor‐
tant than genetic factors in familial aggregation of PD. In maximum PD cases the cause is
environmental influence, probably toxic, overlaid on a background of slow, sustained
neuronal loss due to progressing age [4]. Finding PD in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydro‐
pyridine (MPTP) drug consumers rejuvenated curiosity in reassessing environmental
influences [5]. Another theory of Parkinsonism suggests that genetic predisposition may be
transmitted through mitochondrial inheritance.
Current therapeutic strategies for PD mitigate symptoms by the replacement of dopamine,
with variable efficacy and considerable side effects. Levodopa (L‐dopa), a dopamine precur‐
sor, the leading treatment of PD for over 40 years, improves motor impairment by increas‐
ing dopamine levels [6]. However, continued use of L‐dopa leads to other motor dyskinesias
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that undermine the benefits of treatment. The development of effective treatment for PD is
difficult because pathology is affected by several pathways that may act serially or in paral‐
lel. However, there are currently no established curative, preventative, or disease‐modifying
interventions, stemming from a poor understanding of the molecular mechanisms of patho‐
genesis.
This chapter primarily aims to present an overview of the sporadic PD, disease modeling in
Drosophila and critically analyze the potential opportunities and the notable limitations
associated with fly models. Further, we have also briefly discussed some of the current
applications of the model to obtain insights into the underlying molecular mechanism/s related
to PD.
2. Animal models of Parkinson's disease
Animal models have been invaluable tools for investigating the underlying mechanisms of the
pathogenesis of PD. However, the usefulness of these models is dependent on how precisely
they replicate the features of clinical PD. Nonmammalian models are a great cost‐effective
alternative to rodent and primate‐based models, allowing rapid high‐throughput screening of
novel therapies and investigation of genetic and environmental risk factors. Thus far, the
nonmammalian rotenone models have included worm (Caenorhabditis elegans), fly (Drosophi‐
la), zebrafish (Danio rerio), and pond snail (Lymnea stagnalis). A good model of PD should
exhibit pathological and medical characteristics of PD including both dopaminergic and
nondopaminergic systems, the central and peripheral nervous systems, also the motor and
nonmotor symptoms associated with the disease. Furthermore, the age‐reliant inception and
progression of pathology should be reflected [7].
Contemporary knowledge on the potential pathogenic and pathophysiological mechanisms
of PD derives from innumerable studies conducted, in the past four decades, on experimen‐
tal models of PD. While animal models, in particular, have provided invaluable information,
they also offer the opportunity of trying new therapeutic methods. These model systems have
been traditionally grounded on the exposure of neurotoxins able to imitate many of the
pathological and phenotypic characters of PD in mammals. Conversely in the previous decade,
the dawn of the “genetic era” of PD has provided a significant growth in this field with a
number of transgenic models for experimentation. It is well recognized that both these classes
of animal PD models (genetic and neurotoxin) have their own specificities as well as limita‐
tions and employment of one model or the other depends on the specific questions that are
being addressed.
Genetic models: Animal models are developed primarily based on identified target genes (i.e.,
by mutating or knocking out) associated with potential mechanisms known to cause PD in
humans (Table 1) [8–21]. For example, the autosomal dominant transmission of LRRK2
mutations makes transgenic expression of pathogenic LRRK2 species suitable for modeling
disease process in PD. The invertebrate transgenic models producing LRRK2 PD mutants
phenotypes range from no change to apparent neuronal loss or deficits in DA systems and
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motor behavior [22] that were used to evaluate LRRK2 kinase inhibitors in neuroprotection,
revealing the potential value of the invertebrate LRRK2 models in drug screening [23].
Sym
bol
Gene
locus
Gene Drosophila
homolog
Inheri
tance
Disorder Status
and
remarks
PARK1 4q21‐22 SNCA [10] No
homolog
AD Early‐onset
Parkinsonism
Confirmed
PARK2 6q25.2‐
q27
PARK2
encoding
Parkin[11]
Parkin AR Early onset
Parkinsonism
Confirmed
PARK3 2p13 Unknown – AD Classical
Parkinsonism
Unconfirmed
PARK4 4q21‐
q23
SNCA No homolog AD Early‐onset
Parkinsonism
Erroneous
locus
(identical to PARK1)
PARK5 4p13 UCHL1 Uch AD Classical
Parkinsonism
Unconfirmed
PARK6 1p35‐p36 PINK1 [12] Pink1 AR Early
onset
Parkinsonism
Confirmed
PARK7 1p36 PARK7
encoding
DJ‐1[13]
Dj‐1α
and dj‐1β
AR Early
onset
Parkinsonism
Confirmed
PARK8 12q12 LRRK2 [14] Lrrk AD Classical
Parkinsonism
Confirmed
PARK9 1p36 ATP13A2
[15]
CG32000 AR Kufor–Rakeb
syndrome, a
formof juvenile‐
onset atypical
Parkinsonism with
dementia,
spasticity and
supranuclear gaze
palsy
Confirmed
PARK10 1p32 Unknown – Risk
factor
Classical
Parkinsonism
Confirmed
susceptibility
locus
PARK11 2q36‐27 Unknown – AD Late Not
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Sym
bol
Gene
locus
Gene Drosophila
homolog
Inheri
tance
Disorder Status
and
remarks
(maybe GIGYF2) onset
Parkinsonism
independently confirmed
PARK12 Xq21‐
q25
Unknown – Risk
factor
Classical
Parkinsonism
Confirmed
susceptibility
locus
PARK13 2p12 HTRA2 HtrA2 AD
or
risk
factor
Classical
Parkinsonism
Unconfirmed
PARK14 22q13.1 PLA2G6 [16] iPLA2‐VIA AR Early‐onset
dystonia‐
Parkinsonism
Confirmed
PARK15 22q12‐
q13
FBXO7 [17] No
homolog
AR Early‐onset
Parkinsonian‐
pyramidal
syndrome
Confirmed
PARK16 1q32 Unknown
(maybe RAB7L1)
– Risk
factor
Classical
Parkinsonism
Confirmed
susceptibility
locus
PARK17 16q11.2 VPS35 Vps35 AD Classical
Parkinsonism
Unconfirmed
PARK18 6p21.3 EIF4G1 eIF4G AD Late
onset
Parkinsonism
Unconfirmed
PARK19 1p31.3 DNAJC6 [18] Auxillin AR Juvenile‐
onset
Parkinsonism
Confirmed
PARK20 21q22.11 SYNJ1 [19, 20] Synj AR Early‐
onset
Parkinsonism
Confirmed
AD, autosomal dominant; AR, autosomal recessive (adapted from Marras et al. [21]).
Table 1. Monogenetic forms of PD and its fly homolog(s).
Neurotoxic models: Several studies have been performed to model PD‐associated neuron loss
by neurotoxin intoxication in animals, the most common Parkinsonian neurotoxins being 6‐
hydroxydopamine (6‐OHDA), 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP),
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rotenone, and paraquat [24, 25], and the common neurotoxic models of PD include that
produced by the toxin 6‐hydroxydopamine (6‐OHDA) commonly used in rats, mice and
marmosets, and 1‐methyl‐4‐ phenyl‐1,2,3,6 tetrahydropyridine (MPTP), used in mice and also
in nonhuman primates. Administration of MPTP to animals, such as monkeys, mice, cats, rats,
guinea pigs, dogs, sheep and even frogs and goldfish, has been shown to cause Parkinsoni‐
an‐like motor disturbances [26, 27].
3. Pathophysiology of Parkinson's disease
3.1. Sporadic Parkinson's disease: an overview
A sporadic disease can be explained as a disease occurring randomly in a population with no
known cause. In sporadic PD, the cause is considered to be environmental though the genetic
influence is also present and hence the pathogenesis of PD is likely to be multifactorial which
may involve gene–environment interactions. The discovery of MPTP (1‐methyl‐4‐phenyl‐
1,2,3,6‐tetrahydropyridine), which reproduces pathological features of idiopathic Parkinson‐
ism by targeting the nigrostriatal system [28] and pesticides (such as rotenone and paraquat),
has implicated environmental toxins in the induction of sporadic PD [29, 30]. Both epidemio‐
logical and experimental data suggest the potential involvement of specific agents such as
neurotoxicants (e.g., pesticides) or neuroprotective compounds (e.g., tobacco products) in the
pathogenesis of nigrostriatal degeneration, further supporting a relationship between the
environment and PD [28]. Further, the identification of the mutated α‐synuclein (SCNA) gene
causing familial PD [10] as a risk factor for sporadic disease [31] provides a genetic context for
the disease. The finding of α‐synuclein as a key component of the Lewy body [32] further links
this gene to potential molecular mechanisms of PD.
3.2. Environmental basis of sporadic PD
The study of environmental risk factors for PD is difficult because environmental exposures
and gene–environment interactions may occur well before the onset of clinical symptoms since
it remains undetected for many years. Moreover, the severe neurodegenerative changes that
underlie the symptoms of PD may be the result of synergistic effects of multiple exposures and
these effects could have been compounded by increased vulnerability of the aging nigrostria‐
tal system to toxic injury over the years. Epidemiological and case–control studies suggest that
rural residence, well water consumption, pesticide use, and certain occupations (farming,
mining, and welding) are associated with an increased risk of PD [33–36].
Epidemiological studies have suggested an association with environmental toxins, mainly
mitochondrial complex I inhibitors like rotenone [37, 38]. The results are consistent with a dose‐
dependent effect in agricultural workers and the risk increased with duration of pesticide
use [39, 40]. Data also suggest that exposure to specific pesticide such as bipyridyl, organo‐
chlorine, and carbamate derivatives could have a causal role in PD [39, 41]. Further, chronic
exposure to metals/pesticides is also associated with a younger age at onset of PD among
patients with no family history of the disease and that duration of exposure is a factor in the
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magnitude of this effect [42]. For instance, a study in Taiwan, where the herbicide paraquat
(PQ) is commonly spurted on rice fields, a robust relationship was testified between para‐
quat contact and PD menace and the danger was amplified by more than six times in individ‐
uals who had been exposed to PQ chronically [43].
3.3. Environment toxins and their mechanisms of action
The accidental discovery of MPTP leading to Parkinsonian syndrome stimulated the search
for environmental factors as potential causes of PD. Several epidemiological studies have
suggested that environmental toxins are one of the major causes of sporadic PD [44]. Sporadic
PD's main cause is the accumulation of alpha‐synuclein but by an uncertain causative agent
and uneven occurrence point in age of patients. The mechanisms by which the neurotoxins
induce PD‐like symptoms are briefly described below.
MPTP: MPTP is a metabolite of the drug heroin. It is transported through the blood–brain
barrier (BBB) by the plasma membrane dopamine transporter (DAT) and once it crosses the
blood–brain barrier, MPTP is metabolically activated to the fully oxidized 1‐methyl‐4‐
phenylpyridinium species (MPP+) which is then taken up into dopaminergic neurons via
DAT [45, 46]. After MPP+ gains access into dopaminergic neurons, it is accumulated into
synaptic vesicles via the vesicular monoamine transporter (VMAT2) [47]. The modulation of
MPTP/MPP+ toxicity by DAT and VMAT2, where DAT enhances and VMAT2 protecting
against toxicant injury, provides a paradigm linking environmental exposures to nigrostria‐
tal degeneration. The ratio of DAT to VMAT2 indicates the sensitivity of dopaminergic neurons
to toxic injury [48].
6‐Hydroxy dopamine (6‐OHDA): 6‐OHDA is the first catecholaminergic neurotoxin that was
used to generate animal models of PD. Since this compound cannot cross BBB, it is needed to
be injected and inserted systemically to aim dopamine pathways [49]. On injecting into
substantia nigra, 6‐OHDA causes severe loss of dopamine neurons within a day [50]. Inside
neurons, 6‐OHDA produces reactive oxygen species (ROS) and quinones that inactivate
biological macromolecules. Till now, no Lewy body‐like inclusion has been described in the
6‐OHDA model. Owing to its inability to cross BBB, this model is less popular.
Rotenone (ROT): ROT is used as a broad‐spectrum pesticide and belongs to the family of
isoflavones naturally found in the roots and stems of several plants. Highly lipophilic, it easily
crosses the BBB, and for cellular entry [51], it does not depend on the DAT. Within the cell
rotenone mount up in mitochondria and inhibits complex I (where it impedes the transfer of
electrons from iron–sulfur (Fe–S) centers to ubiquinone). It is opined that augmented ROS
assembly is related with complex I inhibition, which may result in causing oxidative dam‐
age to DNA and proteins of neuronal cells. Further, nitric oxide may interact with ROS,
particularly superoxide and hydroxyl radicals, resulting in peroxynitrite formation, eventu‐
ally leading to cellular defects and impairment of dopaminergic neurons [52]. Further, ROT
was shown to inhibit proteasome activity and dysfunction in proteasomes has been implicat‐
ed in the pathogenesis of both genetic and sporadic forms of PD [53, 54].
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Paraquat (PQ): PQ is one of the most widely used herbicides in the world. The structural
similarity of PQ with 1‐methyl‐4‐phenylpyridinium ion (MPP+) prompted the speculation that
PQ might be dopaminergic neurotoxicant which may lead to PD. PQ is suspected to enter the
brain by neutral amino acid transporters and subsequently the cells in a sodium‐dependent
fashion [55]. Once within cells of the CNS, PQ acts as a redox cycling compound at the cytosolic
level, which potentially leads to indirect mitochondrial toxicity [56]. Recently, it has also been
shown that PQ‐induced apoptosis may involve Bak protein, a pro‐apoptosis Bcl‐2 family
member [57].
Maneb (MB): MB, a commonly used fungicide, is an irritant to respiratory tracts and is capable
of inducing sensitization by skin contact. Mechanistically, MB seems to cross the BBB.
Although knowledge of the mechanisms of this toxin is very limited, MB preferentially inhibits
mitochondrial complex III [58]. Further, MB was shown to induce apoptosis through Bak
activation, whereas combination of PQ and MB inhibits the Bak‐dependent pathway while
potentiating apoptosis through Bak protein [59].
Metals: The potential role of metals due to prolonged exposure as risk factors for Parkinson's
disease has been evaluated [60]. Chronic occupational exposure to high levels of manganese
(Mn) in manganese miners causes accumulation of this metal in the basal ganglia, resulting in
tremors, rigidity and psychosis that resemble PD [61]. The metal‐induced Parkinsonian
syndrome that results from Mn exposure differs significantly from idiopathic PD. The
Parkinsonism caused by Mn does not respond to L‐DOPA treatment and the primary target
of Mn toxicity seems to be the globus pallidus rather than the nigrostriatal system [62]. The
potential role of iron and other transition elements has also been studied. The level of
ferritin (primary intracellular protein capable of keeping iron bound in a nonreactive status)
in the nigral tissue of patients with PD was found to be decreased [63]. Thus, iron accumula‐
tion together with decreased binding capability may enhance the risk for iron‐mediated toxic
reactions in PD by generating the highly toxic hydroxyl radical in the presence of iron and
hydrogen peroxide, thus leading to oxidative stress and ultimately neurodegeneration.
4. Molecular pathways in sporadic PD
Though Mendelian genes are responsible only for a small subset of PD patients, it is speculat‐
ed that the same pathogenetic mechanisms could also play a relevant role in the develop‐
ment of more frequent sporadic PD [64]. With advancement in molecular biotechnological
tools and techniques, a number of genes and proteins linked to PD have been identified, which
reveal a complex network of molecular pathways involved in its etiology, suggesting that
common mechanisms underlie both familial and sporadic forms of PD (Table 2) [65–79]. Three
predominat pathways that can trigger the neurodegenerative process are as follows: (a)
accumulation of aggregated and misfolded proteins, (b) impairment of the ubiquitin protein
pathway (UPS) and the autophagy pathway, and (c) mitochondrial dysfunction [64].
Functional studies on the proteins encoded by PD‐related genes supports these pathways and
it is confirmed by both pathological and biochemical studies performed in patients with
sporadic PD with no apparent genetic cause [80–82]. Further, critical cellular protective
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pathways, such as autophagy, UPS, and mitochondria dynamics, are shown to lose adept‐
ness with increasing age and there is a progressive build‐up of somatic mutations particular‐
ly in the mitochondrial DNA during aging process [64]. Recent studies have shown the role
for chronic neuroinflammation and microglia activation in PD pathogenesis, suggesting that
different molecular/cellular events may contribute to neurodegeneration by activating
resident microglial populations in selected brain areas, with potential detrimental effects on
vulnerable neuronal populations [83].
Compound
treatment
Drosophila
model
Modifies
phenotype(s)
Pathway/
process
References
Sulforaphane and
allyl
Disulfide
parkin DA
neuron
number
Oxidative
stress
[65]
α‐synuclein DA
neuron
number
[65]
S‐Methyl‐
L‐cysteine
α‐synuclein Locomotor
activity
[66]
Polyphenols α‐synuclein Lifespan,
Locomotor activity
[67]
Paraquat
and
Iron
Locomotor
activity
[68]
α‐Tocopherol DJ‐1β Lifespan [69]
PINK1 Ommatidial
degeneration
[70]
SOD PINK1 Ommatidial
degeneration
[70]
Melatonin DJ‐1β Lifespan [69]
Paraquat Locomotor
activity
[71]
Rotenone Locomotor
activity,
Dopamine
neuron number
[71]
Bacopa monieri
leaf extract
Paraquat;
Rotenone
Oxidative markers;
Mitochondrial functions
[72, 73]
Minocycline DJ‐1α DA neuron number,
dopamine levels
Oxidative stress/
inflammatory process
[74]
Celestrol DJ‐1α DA neuron number, [74]
Understanding Pathophysiology of Sporadic Parkinson's Disease in Drosophila Model: Potential Opportunities and
Notable Limitations
http://dx.doi.org/10.5772/63767
225
Compound
treatment
Drosophila
model
Modifies
phenotype(s)
Pathway/
process
References
dopamine levels, Locomotor activity
and survival rate
under oxidative stress
conditions
Rapamycin Parkin/PINK1 Thoracic indentations,
Locomotor activity,
DA neuron number,
and muscle integrity.
TOR
signaling
[75]
Geldanamycin α‐
synuclein
DA neuron
number
Removal of excess
or toxic protein
forms
[76, 77]
Zinc
Chloride
Parkin Life span, Locomotor
activity, and percentage of
adulthood survivors.
Zinc
homeostasis
[78]
Modified from Munoz‐Soriano and Paricio [79].
Table 2. Therapeutic compounds shown to modify phenotype(s) in the Drosophila PD model.
4.1. Genetic basis of sporadic PD
The use of genetically tractable organisms to model gene–environment interactions has
become an efficient means of identifying genetic risk factors [84, 85]. Functional characteriza‐
tion of the genes involved in familial PD has shown significant comprehensions into the
molecular mechanism(s) responsible to the pathogenesis of PD. Abnormal protein and
mitochondrial homeostasis are the crucial factors behind the development of PD, with
oxidative stress playing a vital connection between the two events. Genome‐wide associa‐
tion studies (GWAS) showed variations in α‐synuclein and LRRK2 (well‐known familial PD
genes), i.e., as important risk causes for the sporadic PD [86]. The elevation of dopamine
synthesis in response to a variety of stressors [87] may subject DA neurons to an increased risk
for oxidative stress‐mediated impairment [88]. Nevertheless, connotation studies of polymor‐
phisms within these genes have not proved the hypothesis [89, 90].
The recent application of high throughput whole genome and exome analysis technologies
along with bioinformatics has provided valuable inputs in the identification of novel suscept‐
ibility loci involved in apparent sporadic PD. It is predicted that many more variants re‐
mained to be discovered despite the success of GWAS in discovering novel genetic variants
in PD. In this regard, genome‐wide complex trait analysis [91, 92] may prove useful for a more
exhaustive screening for PD risk variants [93]. Groundbreaking efforts have begun to establish
the relationship between single nucleotide polymorphisms (SNPs) identified by GWAS and
gene expression levels to describe their functional meaning. This approach has provided
significant insights into various potential novel mechanisms underlying the observed SNP
associations with PD etiology.
Challenges in Parkinson's Disease226
4.2. Interaction between genetics and environment
The concept that gene–environment interactions affect PD susceptibility was proposed more
than a decade ago [94]. Although many studies have described positive associations be‐
tween genetic polymorphisms and increased risk for PD, only a few human association studies
have examined gene–environment interactions. Occupational pesticide exposure as well as
high exposure to PQ and MB in carriers of DAT genetic variants was shown to increase the PD
risk [36, 95]. Further, SNP in NOS1 (neuronal nitric oxide synthase 1) and GSTP1 (gluta‐
thione S‐transferase pi 1) have been linked to an increased risk for PD among pesticide‐exposed
individuals [96], although an association between GSTP1 and pesticide exposure has not been
supported by a large cohort study conducted subsequently [97]. However, European studies
did not show noteworthy interaction between polymorphisms in 15 genes that impact
metabolism of extraneous chemicals or dopamine and exposure to pesticides and metals [97].
Twin studies: Twin studies are particularly useful in distinguishing between the influence of
genetics or the environment on the risks of a disease. If genetic factors predominate in etiology
of a disease, it is expected that concordance in monozygotic (MZ) twins will be greater than
dizygotic (DZ) twins. Using striatal 18F[DOPA] positron emission tomography (PET) scan to
detect dopaminergic dysfunction in asymptomatic cotwins of twin pairs with mostly spora‐
dic and late onset PD, Piccini et al. [98] found a three‐fold higher concordance rate of PD in MZ
twins (55%) than in DZ twins (18%), suggesting a significant genetic contribution. Further‐
more, when monitored over a period of 7 years, asymptomatic MZ cotwins all showed
progressive loss of dopaminergic function and four developed clinical PD, while none of the
DZ twin pairs became clinically concordant. Similarly, a recent longitudinal study carried out
on Swedish twins with predominantly sporadic PD revealed concordance rates of 11% for MZ
and 4% for same‐sexed DZ twin pairs, with an overall heritability estimate of 34% [99].
Two‐hit PD models: Present genetic PD models failed to reproduce nigrostriatal DA loss, hinting
that a single genetic risk factor is not sufficient enough and an environmental factor may be
required to initiate the process of neurodegeneration. To understand this paradigm and to
decipher the interaction between genes and environment two hit animal models (animals with
a genetic defect will be exposed to multiple environmental factors/toxicants to study if this
synergy will lead to DA degeneration) will be of potential help.
5. Insights into sporadic PD pathophysiology through Drosophila
The fruit fly Drosophila has emerged as a suitable model for studying mechanisms of PD‐related
neurodegeneration in the past decade. Structural architecture and functional pathways
involved in dopamine synthesis and degradation are well preserved between Drosophila and
human. Transgenic flies (neuronal overexpression of wt or mutant (A53T or A50P) human
alpha‐synuclein) showed age‐dependent and selective loss of dopaminergic neurons, forma‐
tion of fibrillary inclusions containing alpha‐synuclein, as well as a progressive loss of climbing
activity, which could be alleviated by L‐DOPA or DA agonists [100]. Mutational analyses of
alpha‐synuclein in Drosophila have permitted an extended evaluation of the protein domains
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involved and/or required for toxicity showing, for example, that truncated forms of alpha‐
synuclein have a central hydrophobic region, between residues 71 and 82, essential for the
formation of oligomeric and fibrillary forms of the protein and toxicity. Importance of post‐
translational modification of alpha‐synuclein (phosphorylation on serine 129 and tyrosine 125,
on alpha‐synuclein oligomerization and toxicity) was demonstrated using the Drosophila
model. Using fly model it was also shown that early, soluble forms of aggregates of alpha‐
synuclein are more toxic.
Mutations that induce loss of function or inactivation of the fly homologs of mutations of fly
homologs of PINK1, parkin, DJ‐1, or LRKK2 lead to selective DA degeneration leading to
mobility defects that can be characterized through behavioral assays. Drosophila parkin null
mutants exhibit decreased life span, mitochondrial abnormalities, and flight muscle deterio‐
ration leading to mobility defects and diminished proteasome 26S activity. Overexpression of
mutant but not with wild parkin (human gene) in Drosophila leads to dopaminergic deterio‐
ration and motor defects, signifying a dominant negative effect of the mutated protein in PD
pathology. Further, PINK1 mutant flies also share PD characteristics with parkin mutants.
Drosophila models have been important to identify the role of both parkin and PINK1 in the
regulation of mitochondrial physiology [101]. Unlike mammals, Drosophila expresses two DJ‐
1 homologs, viz., DJ‐1 alpha, restricted to male germline, and DJ‐1 beta that, similarly to
mammals, is ubiquitously expressed. Different mutations of both genes have been induced.
DJ‐1beta KO flies showed enhanced susceptibility to cytotoxins, such as paraquat, H2O2, and
rotenone, further supporting the protective redox function of DJ‐1. Similarly, DJ‐1beta
mutations that cause loss of protein function lead to accumulation of ROS in fly's brain.
5.1. Induction of PD in Drosophila
Drosophila were first used to model PD, when Feany and Bender [100] produced transgenic
flies that either expressed normal human α‐synuclein or one of the mutant forms, A30P and
A53T α‐synuclein, which have both been linked to familial PD. This discovery revealed the
potential of Drosophila system for modeling gain and loss‐of‐function genetic mutations that
are associated with PD, thereby allowing the elucidation of the genes molecular functions and
the pathways involved.
5.2. Toxin models of Drosophila for PD
Several environmental chemicals (neurotoxins) have been employed to recapitulate PD‐like
symptoms and pathology in Drosophila system [102]. Drosophila performs motor functions such
as walking, climbing, and flying and has a well‐developed nervous system which makes
Drosophila a suitable model for understanding PD. These kinds of complex behavior pheno‐
types are similar from strain to strain and hence characterizing a toxin induced PD model for
this organism becomes easy [100]. Extensively used chemical models with their salient features
are briefly described below.
Rotenone (ROT) induced PD model in Drosophila: Inhibition of the mitochondrial respiratory
chain by ROT has been widely used to study the role of the mitochondrial respiratory chain
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in apoptosis [103, 104]. The mitochondrial respiratory chain is the major site of ATP produc‐
tion in eukaryotes and it is well recognized that this organelle not only generates ATP, but also
plays an important role in apoptosis [105–107]. It is now clear that upon apoptotic stimula‐
tion mitochondria can release several proapoptotic regulators, including cytochrome c [108],
Smac/Diablo [109, 110], endonuclease G [111], and apoptosis‐inducing factor [112] to the
cytosol. These proapoptotic regulators will then activate cellular apoptotic programs down‐
stream [105–107]. The release of proapoptotic regulators is further regulated by the transloca‐
tion of Bcl‐2 family proteins [113, 114]. Some of the salient pathophysiological features of the
ROT fly model are: (a) being lipophilic, it can easily cross the blood–brain barrier but the final
concentration of rotenone in the brain may probably be much lower than the initial because
of these barriers and the powerful excretion system of flies. They have a tendency to stay at
the bottom of vials and did not appear to coordinate their legs normally [37]. (b) Since neuronal
dopaminergic clusters are normally present in each Drosophila adult brain hemisphere [115–
117], abnormalities are characterized by the disappearance of part or the totality of dopami‐
nergic cell clusters but this effect varies in intensity from one fly to another [37].
Paraquat (PQ) model of PD in Drosophila: Long‐term exposure to environmental oxidative
stressors, such as the herbicide PQ, has been linked to the development of PD. In view of this,
PQ is frequently used in the Drosophila system and other animal models to study PD and the
degeneration of dopaminergic neurons (DNs). Recently, it has been shown that expression of
D1 like dopaminergic receptor (DAMB receptor) was directly proportional to PQ induced
toxicity in CNS of flies [118]. It is notable that a long‐term neuronal DA synthesis decreases
the DAMB expression and resists the PQ toxicity. Age‐related decrement in PQ resistance is
also observed with a significant increase in DAMB receptor. This evidence proves that there
are more areas to be researched regarding DA related neurodegeneration in Drosophila. Some
of the salient pathophysiological features of PQ fly model are: (a) flies exhibit rapid onset of
movement disorders, including resting tremors, bradykinesis, rotational behaviors and
postural instability which resemble Parkinsonian symptoms. Furthermore, the flies frequent‐
ly freeze while attempting to climb vial walls and would often fall to the bottom of the vial.
Males exhibit symptoms 12 hours earlier than females, but both males and females are strongly
affected [71]; (b) PQ‐dependent dopaminergic neuron loss is totally selective in a time‐
dependent loss of exposure where after 6 hours of exposure PPL1 and by 12 hours PPM2, PPM3
cluster will be affected whereas PPM1 and PPL2 clusters only get affected after 20–24 hour of
exposure [71], and (c) changes in the neuronal cell are also a trait where cell bodies aggre‐
gate in a round shape, and fragment and then disappear [71].
6. Application of Drosophila model: screening platform for assessment of
neuroprotective potential
Drosophila models are a great cost‐effective alternative to rodent and primate‐based models,
allowing rapid high throughput screening of novel therapies. Studies done with Drosophila
model coexposed to rotenone and melatonin (an antioxidant and free radical scavenger)
showed that melatonin improved the movement behavior of rotenone‐treated flies, even more
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evidently than L‐dopa [119]. Quantification of the number of dopaminergic cells after 1 week
of rotenone feeding revealed that the presence of melatonin significantly rescued the loss of
neurons in all of the clusters [37]. Subsequently, the rotenone model of Drosophila has been
extensively employed as a screening platform to assess the neuroprotective potential of various
molecules and phytoconstituents. Over the last five years, numerous workers have em‐
ployed the fly rotenone model (both wild type and genetically modified strains) to test
potential neuroprotective treatments [72–73, 120, 121]. The majority of these studies used
compounds that have multiple therapeutic properties such as antioxidant, anti‐inflammato‐
ry, and anti‐apoptotic properties, which largely yielded positive results such as reductions in
ROS and inflammatory mediators, attenuation of TH‐positive neuron loss and striatal
dopamine loss as well as reversal of motor deficits [122].
6.1. Plant‐derived neuroprotective agents in PD
The Drosophila model is extensively used due to the flies’ rapid generation time, low cost, and
amenability for genetic manipulation, and thus serves as an ideal model for identifying
promising neuroprotective candidates that can then undergo further validation in mammali‐
an models (Table 2) [65–79, 123]. Growing evidence indicate that the herbs used in tradition‐
al medicines contain neuroprotective compounds such as resveratol, curcumin or ginsenoside,
green tea polyphenols or catechins, triptolide, etc. [124–128]. These compounds may help
enhancing antioxidant activity, decrease loss of dopamine, inhibit activation of microglia,
reduce the release of pro‐inflammatory factors, prevent α‐synuclein aggregation and fibrilla‐
tion. These herbs also protect the dopaminergic neurons against neurotoxins like MTTP, 6‐
OHDA. Some of the major plant derived molecules suggested as therapeutic agents for PD are
as follows.
Resveratol: This is a polyphenolic compound naturally found in grapes. This is able to cross the
blood–brain barrier and is water soluble [129]. The numerous pharmacological functions
include anti‐inflammation, antiapoptosis, antioxidation, anticancer, etc.
Curcumin: In recent years curcumin has shown therapeutic potential for neurodegenerative
diseases such as PD. It is a natural polyphenol found in the spice turmeric and is known for
several biological and medicinal effects such as anti‐inflammatory, antioxidant, anti‐prolifer‐
ative activities, etc. It is demonstrated to help in preventing the aggregation and fibrillation
of α‐synuclein [130]. Curcumin glucoside, a modified form, prevents the aggregation and
enhances the solubility of α‐synuclein [131]. Studies have shown that curcumin reduces the
LRRK2 kinase activity and decreases the levels of oxidized proteins. Thus curcumin also acts
as an inhibitor for LRRK2 kinase activity. Our laboratory has shown stage‐specific neuropro‐
tective efficacy of curcumin in Drosophila model of idiopathic PD [132].
Ginsenoside: There are two major categories of ginsenosides—protopanaxadiols and protopa‐
naxatriols. In vitro and in vivo studies have shown ginsenosides to exert pharmacological
effects against neuroinflammation, cerebral oxidative stress, radical formation, and apopto‐
sis. It plays a neuroprotective role in regulation of synaptic plasticity, neurotransmitter release,
and neuroinflammatory responses [126].
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Blueberry extracts: Blueberry contains a large amount of polyphenols and has a greater
antioxidant property than most fruits and vegetables. Consumption of blueberry has been
reported to slow down the age‐related functional and physiological deficits [133–135]. Peng et
al. [136] were the first to show the anti‐aging property of blueberry using Drosophila fly model.
The study also showed that supplemented blueberry extracts increased the mRNA levels of
SOD1, SOD2, and CAT in Drosophila. Blueberry extracts can partially reverse the chronic
Paraquat exposure. Blueberry extracts in diet of flies could increase the mean life span, decrease
Paraquat induced mortality, and partially reverse the locomotor deficiency.
7. Notable limitations
Animal models are absolutely necessary for reproducing physiologic and neurosystems
aspects of neurodegenerative disorders. However, animal models are complicated by the
differing expression levels and patterns of expression of target genes, with different promot‐
ers among other issues for genetic models, and complexities of drug administration, drug
distribution, and metabolism for toxin models [79]. Rodent models have faced limitations due
to lack of strong construct (i.e., genotype or intervention) and face validity (i.e., phenotype),
as well as species and strain limitations. In general, toxin‐induced PD models do not recapit‐
ulate the process of progressive neuron loss and the protein aggregation in LBs, due to the
acute nature of the neurotoxin treatment [137, 138], but they have been useful to support the
concept that alterations in mitochondrial biology are essential for the development of PD [139].
However, animal models allow studying a cellular process in the context of a whole organ‐
ism and are thus more reliable.
Research on PD using cell cultures has many advantages in which they allow rapid screen‐
ing for disease pathogenesis and drug candidates. Cellular models can be easily used for
molecular, biochemical, and pharmacological approaches, but they can lead to misinterpreta‐
tion and artifacts. Vice versa limitations include that the survival of neurons is dependent upon
the culture conditions and the cells do not develop their natural neuronal networks. In most
cases, neurons are deprived of the physiological afferent and efferent connections [140].
While there are many advantages of the fly PD model, the most common disadvantage is that
the important pathogenetic factors which are vertebrate‐specific may be ignored in inverte‐
brate models. The differences between mammals and invertebrates represent potential
drawbacks in modeling brain diseases such as PD [141].
8. Potential opportunities
Drosophila melanogaster was the first major complex organism to have its genome sequenced
[142] and after the human genome was sequenced the homology between the two genomes
greatly strengthened to understand human biology and the disease processes as a model [143].
More importantly, 75% of human disease‐related loci have a Drosophila orthologue [144]. Fly
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model are less costly and time consuming to use when compared to mammals due to their
rapid reproduction time and short lifespan [143, 145, 146]. In addition, flies are capable of
performing complex motor behaviors such as walking, climbing, and flying and their brain is
complex enough to make these behaviors relevant to humans [101, 147, 148].
Some of the unique features of the Drosophila model which have been identified are: (a)
Drosophila models are instrumental in exploring the mechanisms of neurodegeneration, with
several PD‐related mutations eliciting related phenotypes including sensitivity to energy
supply and vesicular deformities. These are leading to the identification of plausible cellular
mechanisms, which may be specific to (dopaminergic) neurons and synapses rather than
general cellular phenotypes. (b) Fly models show noncell autonomous signaling within the
nervous system, offering the opportunity to develop our understanding of the way pathogen‐
ic signaling propagates, resembling Braak's scheme of spreading pathology in PD, (c) fly
models link physiological deficits to changes in synaptic structure, and (d) the strong neuro‐
nal phenotypes observed in the fly models permit relevant in vivo drug testing [149]. Another
key feature making Drosophila an attractive model is the range of genetic tools available to
manipulate them and the ease of introducing human genes into the fly enables it to recapitu‐
late the symptoms and progression of human disease in flies [150]. Two approaches em‐
ployed are: the reverse genetic approach wherein a gene is tested for its potential functional role
by using the GAL4/UAS‐system and the forward genetic approach (function of a gene) for
identification of genes based on phenotype, which is useful to understand diseases whose
genetic basis is yet to determined [141]. The genomics era has played a crucial role in direct‐
ing both the functional biology and the in vitro/in vivo modeling of neurodegenerative diseases
in fly model.
9. Future perspectives
Drosophila has been used to model several aspects of neurodegenerative diseases, including
aggregation toxicity of misfolding disease related proteins [151–156]. Ninety‐five percent of
the Parkinson's disease patients suffer from sporadic form. In those sporadic cases, no
indication allows a decided inference about the underlying causes as well as the pathogenic
mechanism involved [101]. The limitations of human genetics make it necessary to use model
system to analyze affected genes and pathways knowledge of which is essential to develop
therapeutic targets. During last three decades, genetically pliable fruit fly Drosophila has been
a great model system to study human neurodegenerative disorders including PD human
genetic screens, and pathological studies have been able to provide limited mechanistic
insights into the molecular processes that determine disease susceptibility or age at onset of
disease [157]. Genetic analysis has identified causative mutations for autosomal‐dominant and
recessive forms of familial PD. Functional studies of these genes have provided great in‐
sights into potential pathogenic mechanisms of inherited forms of PD; however it is unclear
how these may relate to the more common sporadic forms of PD.
Identification of PD risk locus SREBF1 through GWAS (genome‐wide association studies)
analysis and substantiating its biological function as a regulator of mitophagy [158] remarka‐
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bly emphasize the importance and potential to decipher the risk loci for idiopathic PD through
genome‐wide screens in animal models. However, no systematic genome‐wide functional
screens are performed in sporadic PD models. Here lies the importance and necessity to
perform genome‐wide screen to identify the risk locus for idiopathic PD. Comprehensive
efforts in this direction will provide novel insights into the molecular mechanisms behind the
dopaminergic neurodegeneration and also figure out genetic basis for sporadic PD. Here lies
the potential relevance and advantage of fly genetics and available technologies such as UAS‐
Gal4, fly deletion lines, and RNAi lines, which can be of great help to figure out novel players,
pathways, and mechanistic interactions among neurodegenerative disorders. Hence, it is
worth placing future endeavors in this direction.
10. Conclusion
In this chapter, we have provided an overview of current knowledge on the pathophysiolo‐
gy of sporadic PD employing Drosophila system. We also presented the future perspectives on
the subject matter and emphasize the utmost importance for the need to generate comprehen‐
sive data employing genome‐wide association studies in this model that may lead to identifi‐
cation of newer pathways. We also discussed the importance and necessity to reexamine the
strategies/methods of screens to assess the potential of neuroprotective compounds/mole‐
cules employing late life stages that may provide us better answers on successful utilization of
therapeutic compounds in late onset neurodegenerative disorders such as PD.
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